Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

@article{Zou2018CotargetingTC,
  title={Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439},
  author={Yongkang Zou and Z. Qi and W. Guo and L. Zhang and M. Ruscetti and Tanu Shenoy and N. Liu and H. Wu},
  journal={Molecular Cancer Therapeutics},
  year={2018},
  volume={17},
  pages={2091 - 2099}
}
  • Yongkang Zou, Z. Qi, +5 authors H. Wu
  • Published 2018
  • Chemistry, Medicine
  • Molecular Cancer Therapeutics
  • Targeting the PI3K pathway is a promising strategy for treating prostate cancers with PTEN-loss. However, current anti-PI3K therapies fail to show long lasting in vivo effects. We find that not only the PI3Kα- and PI3kβ-isoforms, but also PI3Kδ, are associated with the epithelial–mesenchymal transition (EMT), a critical process distinguishing indolent from aggressive prostate cancer. This suggests that cotargeting PI3Kα/β/δ could preempt the rebound activation of the parallel pathways induced… CONTINUE READING
    4 Citations

    References

    SHOWING 1-10 OF 35 REFERENCES
    HDAC Inhibition Impedes Epithelial-Mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer
    • 71
    Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.
    • 395
    • PDF
    Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance
    • 278
    • Highly Influential
    Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.
    • 420
    • PDF